ALLO vs NCLH · rev $4.6M vs P/E 16, rev $4.97B
Allogene Therapeutics Inc (ALLO) versus Norwegian Cruise Line Holdings Ltd (NCLH) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Latest reported ALLO revenue for 2026-06-30 was $4.6M. Net income was -$85.3M. ALLO currently screens at market cap $258.1M.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
ALLO currently screens at market cap $258.1M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Not investment advice. Open the ALLO and NCLH stock pages for the full models.
Not investment advice.